The first biosimilar Zarxio (Filgrastim-sndz) was approved by the FDA
On Mar. 6, 2015, the FDA approved filgrastim-sndz (Zarxio, Sandoz, Inc.), the first biosimilar product available in the U.S. Zarxio has the same mechanism of action, route of administration, strength, and dosage form as Amgenﾒs Neupogen.
Tags:
Source: U.S. National Library of Medicine
Credit:
